加快药物批准:满足道德标准的要求
Mattia Andreoletti1, Alessandro Blasimme1
1ETH Zurich-Health Sciences and Technology, Zurich, Switzerland.
Bioethics
|June 21, 2023
概括
加速批准 (AA) 为新药提供了更快的途径,但面临着伦理问题. 本研究概述了伦理合理的AA的六个条件,确保患者安全和监管完整性.
科学领域:
- 制药法规 制药法规 制药法规
- 生物伦理学生物伦理学
- 药物开发 药物开发
背景情况:
- 加速批准 (AA) 是一种监管途径,旨在加快对未满足医疗需求的药物审查.
- 最近的争议,例如批准阿杜卡努马布治疗阿尔茨海默病,突出了有关AA的伦理问题.
- 现有的学术研究集中在阿杜卡努马布病例上,但基本上忽视了AA途径本身的伦理维度.
研究的目的:
- 探索加速审批监管途径的伦理考虑.
- 为道德上可接受的AA流程和决策建立一个条件框架.
- 通过加快审查解决学术文献中关于药物批准伦理学的差距.
主要方法:
- 加快审批途径的概念分析.
- 识别和说明AA的六个核心伦理条件.
- 在监管框架内讨论这些道德条件的实际实施策略.
主要成果:
- 已经确定了伦理上可接受的加速批准的六个条件:道德关怀,证据,风险减轻,公正性,可持续性和透明度.
- 这些条件为评估AA决策的道德有效性提供了一个基准.
- 建议采取实际步骤,将这些伦理考虑纳入监管和监督过程.
结论:
- 加速审批流程的道德有效性取决于满足与证据,安全和透明度有关的特定条件.
- 实施这六个道德条件可以增强公众的信任,并确保负责任的药物监管.
- 该框架为评估和改进加速药物批准途径的伦理标准提供了关键的工具.
相关概念视频
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Pharmacovigilance
914
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
914
Drug Control Governance: Regulatory Bodies and Their Impact
195
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
195


